New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
08:42 EDTCLDNCelladon's Mydicar candidate granted breakthrough therapy designation by FDA
Celladon's lead product candidate, Mydicar, has been granted breakthrough therapy designation by the FDA for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative. This designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. Celladon is currently evaluating Mydicar in the Phase 2b CUPID 2 trial to determine its efficacy in reducing the frequency of and/or delaying heart failure-related hospitalizations. The company expects to report results in April 2015.
News For CLDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
14:46 EDTCLDNEMA issues draft guideline on gene therapy medicinal products
Subscribe for More Information
May 15, 2015
09:11 EDTCLDNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Bsquare (BSQR), up 34.2%... Applied Materials (AMAT), up 3.2%. ALSO HIGHER: Trillium Therapeutics (TRIL), up 13% after being initiated with an Outperform at Oppenheimer... Pernix Therapeutics (PTX), up 7.4% after announcing FDA approval of Treximet for use in pediatric patients... Advaxis (ADXS), up 4.4% after being initiated with a Buy at Jefferies... Netflix (NFLX), up 3.3% following a Bloomberg report that the company is in talks to enter China's online video market... Inovalon (INOV), up 2.9% after being upgraded to Buy from Neutral at Goldman. DOWN AFTER EARNINGS: El Pollo LoCo (LOCO), down 12.8%... King Digital (KING), down 8.3%. ALSO LOWER: PlasmaTech (PTBI), down 5.4% after filing to sell 1.93M shares for selling stockholders... Paycom Software (PAYC), down 7% after 8M share Spot Secondary priced at $36.25... Keurig Green Mountain (GMCR), down 5.9% after Keurig Kold investor presentation... 3D Systems (DDD), down 2.4% after CFO transition... Celladon (CLDN), down 5.1% after the CEO says that the company is evaluating strategic options.
May 14, 2015
16:38 EDTCLDNCelladon CEO says evaluating strategic options
"We are in the process of conducting an extensive review of the CUPID2 data in the attempt to better understand the observed negative outcome. Meanwhile, we are conserving our cash resources and are assessing our other previously planned clinical trials and development programs. We are also evaluating our strategic options in order to determine the best path forward to maximize shareholder value," said Krisztina Zsebo, Ph.D., CEO of Celladon.
16:35 EDTCLDNCelladon reports Q1 net loss ($16.7M) vs.($7.2M) in 1Q14
Cash, cash equivalents and investments as of March 31 were $70.6M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use